Quantitative analysis for Gain Therapeutics, Inc. (GANX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (28.0) (grade D). 27 signals analyzed (23 differentiated alt-data).
GANX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $1.90 | $1.71 | $1.76 |
| 2026-05-11 | $1.85 | $1.75 | $1.82 |
| 2026-05-21 | $1.77 | $1.62 | $1.75 |
| 2026-06-03 | $1.85 | $1.76 | $1.79 |
| 2026-06-15 | $1.79 | $1.70 | $1.75 |
| 2026-06-26 | $1.76 | $1.68 | $1.75 |
| 2026-07-09 | $1.87 | $1.79 | $1.82 |
| 2026-07-21 | $1.85 | $1.63 | $1.84 |
| 2026-07-31 | $1.78 | $1.68 | $1.68 |
| 2026-08-12 | $2.17 | $2.01 | $2.12 |
| 2026-08-24 | $2.03 | $1.93 | $2.00 |
| 2026-09-03 | $1.83 | $1.77 | $1.82 |
How Gain Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| VANI | Vivani Medical, Inc. | $70M | — |
| CLNN | Clene Inc. | $71M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $71M | — |
| LIXT | Lixte Biotechnology Holdings, Inc. | $69M | — |
View all Health Care stocks by valuation and signals →
Gain Therapeutics, Inc. (GANX) scores Sell (28.0), and the composite conceals a 73-point disagreement between its dimensions. It is strongest on analyst consensus at 74, and weakest on technicals at 6 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 74 |
| technicals | 6 |
| competitive moat | 1 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Gain Therapeutics, Inc. (GANX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GANX"><img src="https://stoquant.com/badge/GANX.svg" alt="Gain Therapeutics, Inc. (GANX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.